1851 Harbor Bay Parkway
About Exelixis, Inc.
Every Exelixis employee is united in an ambitious cause: to launch innovative medicines that give patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. After operating in the challenging biotech sector for 25 years, we have a proven track record of resiliency in the face of adversity. The success of our lead product has provided a solid commercial foundation allowing us to reinvigorate our research efforts, and grow our team in areas such as Drug Discovery, Clinical Development and Commercial.
As we expand our global partnerships and further reinvest in R&D to help us discover the next breakthrough for difficult-to-treat cancers, we're seeking to add talented, dedicated employees to power our mission.
Cancer is our cause. Make it yours, too.
Stock Symbol: EXEL
635 articles with Exelixis, Inc.
Exelixis, Inc. announced today that its first quarter 2018 financial results will be released on Wednesday, May 2, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
Roche announced it had temporarily halted recruiting patients to its Phase II MODUL clinical trial for metastatic colorectal cancer after four patient deaths. The patients were receiving Tecentriq (atezolizumab) in combination with Exelixis’ MEK inhibitor Cotellic (cobimetinib).
Exelixis’ Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
Exelixis, Inc. announced that its partner Ipsen received validation of the application for variation to the CABOMETYX® (cabozantinib) marketing authorization from the European Medicines Agency (EMA) for the addition of a new indication for patients with previously treated advanced hepatocellular carcinoma (HCC).
Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
– In the pivotal phase 3 CELESTIAL trial, CABOMETYX provided a statistically significant and clinically meaningful improvement versus placebo in overall survival (OS) –
Exelixis Announces Results from a Phase II Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
The results were the subject of a news briefing that took place earlier today and will be presented during an oral session on February 16 starting at 1:30 p.m. MT at the 2018 Multidisciplinary Head and Neck Cancers Symposium, which is being held in Scottsdale, Arizona, February 15–17, 2018.
Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018
Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
Exelixis Announces Presentation of Updated Phase Ib Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Exelixis today announced the presentation of updated results from the Genentech-sponsored phase 1b clinical trial of cobimetinib (COTELLIC), an Exelixis-discovered MEK inhibitor, in combination with atezolizumab (TECENTRIQ), an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, in patients with metastatic colorectal cancer (CRC).
The data will be presented during an oral session on Friday, January 19 at the 2018 ASCO-GI.
Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
The webcast event will be held following the closing of the ASCO-GI day's sessions on Friday, January 19, 2018, beginning at 9:30 p.m. EST / 6:30 p.m. PST.
Exelixis and StemSynergy Enter Into Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies
The agreement is part of Exelixis’ ongoing strategy to build an innovative pipeline beyond its two internally-discovered, commercially available compounds, cabozantinib and cobimetinib.
Exelixis Announces Amendment to Clinical Research Protocol for Phase Ib Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Exelixis today announced an amendment to the protocol for the phase 1b trial of cabozantinib in combination with atezolizumab (TECENTRIQ) in patients with locally advanced or metastatic solid tumors.
Exelixis Announces U.S. FDA Approval of CABOMETYX (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
RCC is the most common form of kidney cancer in adults.
Exelixis Announces Phase III CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium
Exelixis to submit supplemental New Drug Application to the FDA in the first quarter of 2018.
During the third quarter of 2017, CABOMETYX generated $90.4 million in net product revenue.
Exelixis announced today that its third quarter 2017 financial results will be released on Wednesday, November 1, 2017.
Cabometyx hit key endpoints of overall survival in its Phase III liver cancer trial and investors are overjoyed.
Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma
Exelixis, Inc. today announced that the U.S. Food and Drug Administration has determined the company's supplemental New Drug Application (sNDA) for CABOMETYX (cabozantinib) for patients with previously untreated advanced renal cell carcinoma (RCC) to be sufficiently complete to permit a substantive review.
Exelixis To Receive Milestone Payment From Bristol-Myers Squibb For Submission Of Clinical Trial Authorization For Roryt Inverse Agonist Program
Exelixis Provides Update On Collaborator Daiichi Sankyo, Inc.’s Phase III Clinical Progress With Esaxerenone (CS-3150), Including Positive Top-Line Results And Additional Pivotal Study